Cardioviva™ is the subject of an article on usprobiotic.org regarding an update on cholesterol lowering probiotics
Montreal, Quebec - In a recent article written by Dr. Mary Ellen Sanders entitled: Update on Cholesterol-Lowering Probiotics published on usprobiotics.org, Dr. Sanders writes "...until recently, there has not been many convincing randomized, controlled trials that document specific probiotic-induced improvements in blood lipids. A recent study suggests that certain probiotics might improve blood lipid profiles. Jones et al. 2012 testes the effect of feeding hypercholesterolemic adults yogurt containing microencapsulated Lactobacillus reuteri NCIMB 30242. A total of 114 subjects, divided between probiotic and placebo group, participated in this study. After a 6 week intervention period, changes in LDL-cholesterol (8.92%) and total cholesterol (4.81%) were attained compared to placebo. Results of this magnitude are meaningful and appropriate for a functional food.” she goes on to say that “Results from this study dovetail with recent suggestions of a role for the microbiota in metabolic syndrome. Obesity and diabetes are characterized by altered gut microbiota; furthermore, altered gut microbiota can be reversed by dieting and related weight loss (reviewed in Delzenne et al. 2011). Surely the relationship is a complex one, involving host, microbial and environmental factors. But understanding the role of microbes – both ones we harbor and ones we consume – in metabolic syndrome may provide an unexpected approach to managing this important health concern.” http://cdrf.org/2012/09/07/update-on-cholesterol-lowering-probiotics/ Dr. Mitchell Jones commented that 'while the yogurt result was good at 6 weeks the in press data showing a 11.64% change in LDL-C, 9.14% change in total cholesterol, significant changes in apoB-100, non-HDL-C, fibrinogen and CRP, no change in HDL and no adverse events or changes in safety parameters. In addition, there were benefits in gastrointestinal health as measured by gastrointestinal questionnaire (ROME III). Additional clinical studies will be conducted in 2012 by Micropharma and in conjunction with commercial partners.
Cardioviva™ is a probiotic bacteria of the genus and species Lactobacillus reuteri. It acts through its capacity to produce bile salt hydrolase (BSH) enzyme and supports healthy cholesterol levels by decreasing absorption of dietary cholesterol and increasing metabolic elimination of cholesterol from the blood. Cardioviva™ has been shown to effectively support healthy cholesterol (TC)*, low-density lipoprotein cholesterol (LDL-C), apolipoprotien B 100 (ApoB-100), and non-high density lipoprotein cholesterol (non-HDL-C) in human clinical trials. In addition to its cholesterol-lowering properties, Cardioviva™ provides traditional probiotic benefits such as improved digestive health and immune function.
*For the maintenance of cholesterol levels that are within the normal range.
Micropharma Limited, headquartered in Montreal, Quebec, is bringing a new approach to the development of OTC healthcare products, medical foods, and biotherapeutics. Through innovative research and development, Micropharma is creating scientifically powerful products. Micropharma applies a pathophysiological driven method to developing probiotic and enzyme therapies by focusing first on the heath concern and then developing the effective products to support heath in that condition. This method is supported by extensive research and development to ensure that we are providing the most effective product to consumers. Micropharma is currently addressing probiotic support for some of the World’s most difficult and costly diseases including heart disease, diabetes, chronic liver disease, and hypertension. Our experience research team is supported by a growing business development and marketing group. By fostering strategic partnerships with leading manufacturers, distributors, and retailers, Micropharma is building a global network to deliver innovative and effective health-care solutions.